Synthesis, characterization and biomolecular interactions of Cu(II) and Ni(II) complexes of acyclic Schiff base ligand

Theoretical and experimental investigation of anticancer activities of an acyclic and symmetrical compartmental Schiff base ligand and its Co(ii), Cu(ii) and Zn(ii) complexes

“…In addition to the expected biological properties of the Schiff base compounds, [30][31][32][33][34][35] binding the cobalt, copper and zinc atoms to this unit make these complexes a good prospect for biologically active compounds [36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] (31)(32)(33)(34)(35) for zinc, 36-40 for cobalt, 41-45 for copper). For the study of the biological activities of new ligand (H 3 L Br ) and its complexes 1-3, docking calculations were run to investigate the possibility of interaction between these compounds with nine protein targets, including: BRAF kinase, cathepsin B (CatB), DNA gyrase, histone deacetylase (HDAC7), recombinant human albumin (rHA), ribonucleotide reductases (RNR), thioredoxin reductase (TrxR), thymidylate synthase (TS), topoisomerase II (Top II).…”

(Pyrazolyl)pyridine ruthenium(III) complexes: Synthesis, kinetics of substitution reactions with thiourea and biological studies

“…Therefore, to have a better understanding of the mechanisms and mode of action of metallo-drugs, a combination of experimental and theoretical platforms is critical and is currently being explored. These include studying the kinetics of substitution reactions [5] with biologically relevant molecules, molecular docking [6] and DNA binding studies [7].…”

“…The minimal cytotoxicity of both the ligands and their complexes 1-3 as revealed by their relatively high IC50 values may be due to minimal aromaticity of the (pyrazolyl)pyridineligands, which ultimately limits the interaction of the compounds with the DNA[20]. While there is no well documented relationship between ligand substitution reactions and anti-cancer activity, the favourable reactions of complexes 1-3 with TU may lead to cytoplasmic deactivation of the compounds before reaching the targeted DNA molecule[6]. Another factor that may account for the low activity of the compounds could be the resistant nature of the HeLa cell line compared to other cancer cell types[21].…”

Zinc Complexes with Nitrogen Donor Ligands as Anticancer Agents

“…Schiff base compounds are expected to exhibit biological properties [ 174 , 183 , 184 , 185 , 186 , 187 , 188 ] and their coordination complexes cobalt [ 174 , 189 , 190 , 191 , 192 ], copper [ 174 , 193 , 194 , 195 , 196 ] and zinc [ 174 , 196 , 197 , 198 , 199 ] acceptors are promising pharmacologically active metal compounds.…”